Filing Details
- Accession Number:
- 0001140361-11-038440
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-07-29 09:58:30
- Reporting Period:
- 2011-07-27
- Filing Date:
- 2011-07-29
- Accepted Time:
- 2011-07-29 09:58:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1184149 | W Jonathan Ayers | One Idexx Drive Westbrook ME 04092 | Chairman, President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2011-07-27 | 20,000 | $12.60 | 307,618 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2011-07-27 | 9,300 | $83.07 | 298,318 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2011-07-27 | 4,000 | $83.97 | 294,318 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2011-07-27 | 1,700 | $84.77 | 292,618 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2011-07-27 | 20,000 | $0.00 | 20,000 | $12.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 140,320 | 2012-01-28 | No | 4 | M | Direct |
Footnotes
- The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/03/2011.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $82.60 to $83.59, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $83.60 to $84.32, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $84.60 to $84.91, nclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (01/28/2003) of the date of grant.
Billionaire Hedge Funds
